Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Three More Phase II Trials Under Way
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
